You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
High-grade osteosarcoma arising from a clinically aggressive infantile fibrosarcoma
  1. Larissa V Furtado1,
  2. Teresa Santiago1,
  3. Zachary R Abramson2,
  4. Marija Kacar3,
  5. Zonggao Shi4,
  6. Selene C Koo1,
  7. Robert E Ruiz1,
  8. Roya Mostafavi5,
  9. Matthew J Krasin6,
  10. Barry Shulkin2,
  11. Lindsay J Talbot7,
  12. Alberto S Pappo3,
  13. Jessica Gartrell3
  1. 1 Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  2. 2 Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  3. 3 Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  4. 4 Department of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  5. 5 Division of Cancer Predisposition, Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  6. 6 Department of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  7. 7 Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee, USA
  1. Correspondence to Dr Larissa V Furtado; larissa.furtado{at}stjude.org

https://doi.org/10.1136/jcp-2024-209384

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Introduction

    Infantile fibrosarcoma (IFS) is a soft tissue tumour of intermediate malignant potential that commonly affects the extremities of young children and is characterised by an ETV6::NTRK3 fusion.1 2

    Recurrent copy number changes, including the gain of chromosomes 8, 17 and 20, have been reported in IFS,3–5 but pathogenic mutations in other pathways are rare in this tumour type.6

    We previously reported on a 5-year-old male patient with IFS of the right gluteal region/pelvis treated with chemotherapy, radiotherapy and TRK inhibition who developed metastatic, progressive disease with multiple acquired mutations, including TP53, SUFU and an NTRK F617L gatekeeper mutation.7 Due to acquired larotrectinib resistance, he was started on repotrectinib (according to phase I/II study NCT04094610 protocol).8 In this follow-up report, we describe the transformation (dedifferentiation) of the patient’s IFS to a high-grade osteosarcoma.

    Report

    The patient initially presented at 5 months of age with a mass on the right buttocks. Histological assessment of the ultrasound-guided biopsy tissue showed a cellular spindle cell neoplasm, which was positive for ETV6 rearrangement by fluorescence in situ hybridisation (FISH) and had an ETV6::NTRK3 fusion identified by reverse transcriptase PCR (RT-PCR), supporting a diagnosis of IFS (figure 1A).

    Figure 1

    Morphological and phenotypic progression of a case of recurrent and metastatic infantile fibrosarcoma with multiple acquired mutations and dedifferentiation to high-grade osteosarcoma. Initial biopsy showed a well-vascularised malignant fibroblastic neoplasm composed of a monomorphic population of spindled cells with eosinophilic cytoplasm and round-to-elongated nuclei (A); p53 stain was positive in less than 10% of tumour cell nuclei (G). Post-therapy sample (17 months from initial diagnosis) showed dense collagenisation and rare atypical cells (B); p53 stain was positive in rare tumour cell nuclei (H). Increased cytological atypia over time and p53 overexpression in nearly all tumour nuclei were seen on specimens taken at 36 …

    View Full Text

    Footnotes

    • Handling editor David Creytens.

    • Contributors LVF and TS conceptualised the study. JG, RM, LJT, MK and ASP provided clinical care of the patient and clinical data. TS, SCK and RER performed histopathological evaluation and provided histopathology data. LVF and ZS analysed the molecular data. LVF interpreted the molecular data and wrote the original draft. TS and ZRA assembled the figures. All authors reviewed the writing and edited the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.